Overview
Tab Title Description
Study IDs
Site IRB
- Rochester, Minnesota: 20-004515
About this study
The primary purpose of this study is to understand how epilepsy patients think about neuromodulation in relation to concepts of neuroexceptionalism and the self.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Is 18 years or older, or is 13 years or older with a parent or guardian to participate in the study as a dyad or triad.
- Has a diagnosis of drug-resistant epilepsy and is going to be seen or has already been seen in the Mayo Clinic Neuromodulation Clinic.
- Pre-implantation or longitudinal cohort: Is considering a neuromodulation device but has not been implanted.
- Post-implantation: underwent device implantation between 1 year and 18 months post-interview.
Exclusion Criteria:
- Has had resective surgery on their brain to treat their epilepsy.
- Does not fall into the diagnostic or age categories listed in the inclusion criteria.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Rochester, Minn.
Mayo Clinic principal investigator Richard Sharp, Ph.D. |
Closed for enrollment |
|
More information
Publications
Publications are currently not available